TD Private Client Wealth’s CureVac CVAC Stock Holding History

TD Private Client Wealth’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11	Closed	-$809	–	1219
2021 Q2	$809	Buy	+11	New	+$1.1K	﹤0.01%	1137

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

TD Private Client Wealth's CVAC Position: Q3 2021 in Review

TD Private Client Wealth sold out of CureVac (CVAC) in Q3 2021, closing a stake of 11 shares — an estimated $809 sold.

TD Private Client Wealth first reported a position in CVAC in Q2 2021 and held it in 1 quarter. The position peaked at $809 in Q2 2021. 111 funds tracked by Wall St. Rank hold CVAC as of Q3 2021.

TD Private Client Wealth reported no remaining CureVac position as of Q3 2021 after selling out during the quarter.
TD Private Client Wealth sold 11 CureVac shares in Q3 2021, an estimated $809.
TD Private Client Wealth first reported a position in CureVac in Q2 2021 and held it in 1 quarter.
TD Private Client Wealth's CureVac position peaked at $809 in Q2 2021.
111 funds tracked by Wall St. Rank held CureVac as of Q3 2021.

Based on TD Private Client Wealth's 13F filing for Q3 2021, filed 16 Aug 2024.